# EDGAR Filing Document

**Accession Number:** 0001800373
**File Stem:** 0000000000-23-000747
**Filing Date:** 2023-1
**Character Count:** 4168
**Document Hash:** 160d506855e349a34aefe0f66cf1e741
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000747.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0000000000-23-000747

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230123

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GOLDENWELL BIOTECH, INC.
- **CENTRAL INDEX KEY:** 0001800373
- **STANDARD INDUSTRIAL CLASSIFICATION:** FOOD & KINDRED PRODUCTS [2000]
- **IRS NUMBER:** 842896086
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 2071 MIDWAY DR.
- **CITY:** TWINSBURG
- **STATE:** OH
- **ZIP:** 44087
- **BUSINESS PHONE:** 440-666-7999

**MAIL ADDRESS:**
- **STREET 1:** 2071 MIDWAY DR.
- **CITY:** TWINSBURG
- **STATE:** OH
- **ZIP:** 44087

## Text-Extract

```

United States securities and exchange commission logo

                      January 23, 2023

       Shuang Liu
       Chief Executive Officer, President, and Director
       Goldenwell Biotech, Inc.
       2071 Midway Drive
       Twinsburg, OH 44087

                                                        Re: Goldenwell Biotech,
Inc.
                                                            Form 10-K for the
Fiscal Year ended December 31, 2021
                                                            Filed April 1, 2022
                                                            File No. 000-56275

       Dear Shuang Liu:

               We issued comments to you on the above captioned filing on
October 19, 2022. As of
       the date of this letter, these comments remain outstanding and
unresolved. We expect you to
       provide a complete, substantive response to these comments by February
6, 2023.

               If you do not respond, we will, consistent with our obligations
under the federal securities
       laws, decide how we will seek to resolve material outstanding comments
and complete our
       review of your filing and your disclosure. Among other things, we may
decide to release
       publicly, through the agency's EDGAR system, all correspondence,
including this letter, relating
       to the review of your filings, consistent with the staff's decision to
publicly release comment and
       response letters relating to disclosure filings it has reviewed.

              Please contact Joe Klinko at (202) 551-3824 or Lily Dang at (202)
551-3867 with any
       questions regarding this letter or the comments in the letter referenced
above.

                      Sincerely,

                      Division of Corporation Finance

                      Office of Energy & Transportation

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 23, 2023

Shuang Liu
Chief Executive Officer, President, and Director
Goldenwell Biotech, Inc.
2071 Midway Drive
Twinsburg, OH 44087

Re: Goldenwell Biotech, Inc.
Form 10-K for the Fiscal Year ended December 31, 2021
Filed April 1, 2022
File No. 000-56275

Dear Shuang Liu:

We issued comments to you on the above captioned filing on October 19, 2022. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by February 6, 2023.

If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filing and your disclosure. Among other things, we may decide to release publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filings, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed.

Please contact Joe Klinko at (202) 551-3824 or Lily Dang at (202) 551-3867 with any questions regarding this letter or the comments in the letter referenced above.

Sincerely,

Division of Corporation Finance
Office of Energy & Transportation